These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23286841)

  • 41. How to optimize current therapy of HCV genotype 1 infection with boceprevir.
    Bourlière M; Adhoute X; Wendt A; Ansaldi C; Oules V; Castellani P
    Liver Int; 2014 Feb; 34 Suppl 1():4-10. PubMed ID: 24373071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
    Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.
    González-Colominas E; Broquetas T; Retamero A; García-Retortillo M; Cañete N; Coll S; Pellicer R; Giménez MD; Cabrero B; Bory F; Knobel H; Salas E; Solà R; Carrión JA
    Liver Int; 2015 May; 35(5):1557-65. PubMed ID: 25385188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P; Ho E; Francque S
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
    Shiffman ML; Benhamou Y
    Liver Int; 2013 Feb; 33 Suppl 1():105-10. PubMed ID: 23286853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Telaprevir for chronic hepatitis C virus infection.
    Jesudian AB; Jacobson IM
    Clin Liver Dis; 2013 Feb; 17(1):47-62. PubMed ID: 23177282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
    Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
    J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
    Kwo PY; Lawitz EJ; McCone J; Schiff ER; Vierling JM; Pound D; Davis MN; Galati JS; Gordon SC; Ravendhran N; Rossaro L; Anderson FH; Jacobson IM; Rubin R; Koury K; Pedicone LD; Brass CA; Chaudhri E; Albrecht JK;
    Lancet; 2010 Aug; 376(9742):705-16. PubMed ID: 20692693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?
    Foster GR; Serfaty LD
    Liver Int; 2012 Feb; 32 Suppl 1():61-3. PubMed ID: 22212574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review.
    Pecoraro V; Cariani E; Villa E; Trenti T
    Eur J Clin Invest; 2016 Aug; 46(8):737-48. PubMed ID: 27376688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [New agents for the treatment of hepatitis C].
    Buti M; Homs M
    Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):147-50. PubMed ID: 22118805
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.
    Bruno S; Bollani S; Zignego AL; Pascasio JM; Magni C; Ciancio A; Caremani M; Mangia A; Marenco S; Piovesan S; Chemello L; Babudieri S; Moretti A; Gea F; Colletta C; Perez-Alvarez R; Forns X; Larrubia JR; Arenas J; Crespo J; Calvaruso V; Ceccherini Silberstein F; Maisonneuve P; Craxì A; Calleja JL;
    J Viral Hepat; 2015 May; 22(5):469-80. PubMed ID: 25311757
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiviral strategies in hepatitis C virus infection.
    Sarrazin C; Hézode C; Zeuzem S; Pawlotsky JM
    J Hepatol; 2012; 56 Suppl 1():S88-100. PubMed ID: 22300469
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How to optimize HCV therapy in genotype 1 patients: management of side-effects.
    Chopra A; Klein PL; Drinnan T; Lee SS
    Liver Int; 2013 Feb; 33 Suppl 1():30-4. PubMed ID: 23286843
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HCV therapy in HIV-infected patients.
    Sulkowski MS
    Liver Int; 2013 Feb; 33 Suppl 1():63-7. PubMed ID: 23286848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies.
    Saxena V; Terrault N
    Curr Opin Organ Transplant; 2012 Jun; 17(3):216-24. PubMed ID: 22476221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Boceprevir: a user's guide.
    Kwo PY; Zhao R
    Clin Liver Dis; 2011 Aug; 15(3):537-53. PubMed ID: 21867935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting.
    Maasoumy B; Port K; Markova AA; Serrano BC; Rogalska-Taranta M; Sollik L; Mix C; Kirschner J; Manns MP; Wedemeyer H; Cornberg M
    PLoS One; 2013; 8(2):e55285. PubMed ID: 23383319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new era of hepatitis C therapy begins.
    Jensen DM
    N Engl J Med; 2011 Mar; 364(13):1272-4. PubMed ID: 21449791
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.